Ziegler Capital Management’s BioLife Solutions BLFS Stock Holding History

Ziegler Capital Management’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,106	Closed	-$7.98M	–	424
2020 Q4	$7.98M	Buy	200,106 +5,241	+3%	+$179K	0.26%	147
2020 Q3	$5.64M	Buy	+194,865	New	+$4.21M	0.22%	163

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ziegler Capital Management's BLFS Position: Q1 2021 in Review

Ziegler Capital Management sold out of BioLife Solutions (BLFS) in Q1 2021, closing a stake of 200,106 shares — an estimated $7.98M sold.

Ziegler Capital Management first reported a position in BLFS in Q3 2020 and held it in 2 quarters. The position peaked at $7.98M in Q4 2020. 132 funds tracked by Wall St. Rank hold BLFS as of Q1 2021.

Ziegler Capital Management reported no remaining BioLife Solutions position as of Q1 2021 after selling out during the quarter.
Ziegler Capital Management sold 200,106 BioLife Solutions shares in Q1 2021, an estimated $7.98M.
Ziegler Capital Management first reported a position in BioLife Solutions in Q3 2020 and held it in 2 quarters.
Ziegler Capital Management's BioLife Solutions position peaked at $7.98M in Q4 2020.
132 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2021.

Based on Ziegler Capital Management's 13F filing for Q1 2021, filed 29 Apr 2021.